 ROCKVILLE, Md., Feb. 08, 2021 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today announced it has resubmitted its New Drug Application NDA for SPN-812 for the treatment of ADHD in pediatric patients. The U.S. Food and Drug Administration FDA issued a Complete Response Letter CRL regarding the NDA in November 2020 indicating that the review cycle for the application was incomplete and that the application was not ready for approval in its present form. Supernus and the FDA held a Type A meeting in January 2021 to discuss the CRL and the requirements for the NDA resubmission. 